The 3 analysts offering 12-month price forecasts for Outlook Therapeutics Inc have a median target of 6.00, with a high estimate of 7.75 and a low estimate of 6.00. The median estimate represents a +463.38% increase from the last price of 1.07.
Is outlook Therapeutics (OTLK) stock a buy or sell?
According to the issued ratings of 2 analysts in the last year, the consensus rating for Outlook Therapeutics stock is Buy based on the current 2 buy ratings for OTLK. The average twelve-month price target for Outlook Therapeutics is $6.00 with a high price target of $6.00 and a low price target of $6.00.
What price target do analysts set for OTLK?
What price target have analysts set for OTLK? 4 brokers have issued 1-year price targets for Outlook Therapeutics’ shares. Their forecasts range from $5.00 to $8.00. On average, they expect Outlook Therapeutics’ stock price to reach $6.33 in the next twelve months.
What is the price targets for Outlook Therapeutics?
The average twelve-month price target for Outlook Therapeutics is $6.00 with a high price target of $6.00 and a low price target of $6.00. Learn more Do Wall Street analysts like Outlook Therapeutics more than its competitors? Analysts like Outlook Therapeutics stock more than the stock of other Medical companies.
What is outlook Therapeutics'(OTC) stock price potential upside?
Their forecasts range from $6.00 to $6.00. On average, they anticipate Outlook Therapeutics’ stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 359.8% from the stock’s current price.
Is OTLK stock a good buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: OTLK) stock is to Strong Buy OTLK stock.
Will Gemini Therapeutics stock go up?
The 3 analysts offering 12-month price forecasts for Gemini Therapeutics Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 1.50. The median estimate represents a +36.05% increase from the last price of 1.47.
Is Gemini Therapeutics a good buy?
Gemini Therapeutics has received a consensus rating of Hold. The company’s average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Is Gemini Therapeutics a buy?
The consensus rating for Gemini Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how GMTX compares to other companies.
Should I buy or sell Outlook Therapeutics stock right now?
1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Outlook Therapeutics in the last twelve months. There are currently 1 buy…
What is Outlook Therapeutics’ stock price forecast for 2022?
1 Wall Street research analysts have issued twelve-month price targets for Outlook Therapeutics’ stock. Their forecasts range from $6.00 to $6.00….
How has Outlook Therapeutics’ stock performed in 2022?
Outlook Therapeutics’ stock was trading at $1.36 at the beginning of 2022. Since then, OTLK stock has decreased by 31.1% and is now trading at $0.9…
When is Outlook Therapeutics’ next earnings date?
Outlook Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for…
How were Outlook Therapeutics’ earnings last quarter?
Outlook Therapeutics, Inc. (NASDAQ:OTLK) issued its earnings results on Friday, May, 13th. The company reported ($0.09) earnings per share for the…
When did Outlook Therapeutics’ stock split? How did Outlook Therapeutics’ stock split work?
Outlook Therapeutics’s stock reverse split on Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number o…
Who are Outlook Therapeutics’ key executives?
Outlook Therapeutics’ management team includes the following people: Mr. Ralph H. Thurman , Independent Exec. Chairman (Age 73) Mr. C. Russell T…
Who are some of Outlook Therapeutics’ key competitors?
Some companies that are related to Outlook Therapeutics include Arcellx (ACLX) , Kymera Therapeutics (KYMR) , Editas Medicine (EDIT) , Replimun…
What other stocks do shareholders of Outlook Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPhar…
What is Outlook Therapeutics’s consensus rating and price target?
According to the issued ratings of 1 analysts in the last year, the consensus rating for Outlook Therapeutics stock is Buy based on the current 1 b…
Do Wall Street analysts like Outlook Therapeutics more than its competitors?
Analysts like Outlook Therapeutics stock more than the stock of other Medical companies. The consensus rating score for Outlook Therapeutics is 3.0…
Do MarketBeat users like Outlook Therapeutics more than its competitors?
MarketBeat users like Outlook Therapeutics stock more than the stock of other Medical companies. 70.00% of MarketBeat users gave Outlook Therapeuti…
Does Outlook Therapeutics’s stock price have much upside?
According to analysts, Outlook Therapeutics’s stock has a predicted upside of 337.96% based on their 12-month price targets.
Stock Price Forecast
Analyst Recommendations
The 3 analysts offering 12-month price forecasts for Outlook Therapeutics Inc have a median target of 7.25, with a high estimate of 8.00 and a low estimate of 6.00. The median estimate represents a +339.39% increase from the last price of 1.65.
How much is Outlook Therapeutics stock worth in 2021?
The current consensus among 3 polled investment analysts is to Buy stock in Outlook Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Buy rating. Move your mouse over past
months for detail
Is Outlook Therapeutics a negative stock?
The Outlook Therapeutics Inc. stock price gained 4.80% on the last trading day (Friday, 9th Jul 2021), rising from $2.50 to $2.62. During the day the stock fluctuated 6.46% from a day low at $2.48 to a day high of $2.64. The price has risen in 7 of the last 10 days and is up by 9.62% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 152 thousand more shares were traded than the day before. In total, 937 thousand shares were bought and sold for approximately $2.46 million.
Is Outlook Therapeutics Inc. stock A Buy?
Outlook Therapeutics Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.
Outlook Therapeutics (NASDAQ:OTLK) Price Target and Consensus Rating
Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term.
Analyst Ratings By Month
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst’s rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Average Share Price and Price Target by Month
The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Outlook Therapeutics (NASDAQ:OTLK) Analyst Ratings Frequently Asked Questions
The chart below shows how a company’s share price and consensus price target have changed over time. The dark blue line represents the company’s actual price. The lighter blue line represents the stock’s consensus price target.
OTLK earnings per share forecast
According to the issued ratings of 1 analysts in the last year, the consensus rating for Outlook Therapeutics stock is Buy based on the current 1 buy rating for OTLK. The average twelve-month price target for Outlook Therapeutics is $6.00 with a high price target of $6.00 and a low price target of $6.00. Learn more
on OTLK’s analyst rating history
OTLK revenue forecast
What is OTLK ‘s earnings per share in the next 3 years based on estimates from 1 analyst?
OTLK Stock Trend
What is OTLK ‘s revenue in the next 3 years based on estimates from 1 analyst?
Golden Star Signal
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.
Stock Podcast
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Outlook Therapeutics After-Hype Price Prediction Density Analysis
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Outlook Therapeutics Estimiated After-Hype Price Volatility
As far as predicting the price of Outlook Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range.
Outlook Therapeutics Stock Price Prediction Analysis
In the context of predicting Outlook Therapeutics’ stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Outlook Therapeutics’ historical news coverage.
Outlook Therapeutics Hype Timeline
Have you ever been surprised when a price of a company such as Outlook Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Outlook Therapeutics backward and forwards among themselves.
Outlook Therapeutics Related Hype Analysis
Outlook Therapeutics is now traded for 1.64. The entity has historical hype elasticity of -0.04 and average elasticity to hype of competition of -0.23. Outlook is expected to decline in value after the next headline with price expected to drop to 1.56. The average volatility ofmedia hypeimpact on the company stock price is over 100%.
Outlook Therapeutics Additional Predictive Modules
Having access to credible news sources related to Outlook Therapeutics’ direct competition is more important than ever and may enhance your ability to predict Outlook Therapeutics’ future price movements.